Development of 225Ac Production from Low Isotopic Dilution 229Th

The promise of( 225)Ac targeted alpha therapies has been on the horizon for the last two decades. TerraPower Isotopes are uniquely suited to produce clinically relevant quantities of Ac-225 through the decay of Th-229. Herein, a rapid processing scheme to isolate radionuclidic and radioisotopically pure( 225)Ac in good yield (98%) produced from Th-229 that contains significant quantities of Th-228 activity is described. The characterization of each step of the process is presented along with the detailed characterization of the resulting Ac-225 isotopic starting material that will support the cancer research and development efforts.